Eli Lilly CEO Highlights Growing Market Share for Oral GLP-1 Pill Foundayo
Eli Lilly CEO Dave Ricks highlighted a significant shift in the oral GLP-1 medication market, noting that one-third of new patients are now choosing Eli Lilly's pill, Foundayo. This growth is attributed to its convenience compared to injectable alternatives and Novo Nordisk’s existing oral semaglutide option, which requires fasting before administration. Foundayo removes barriers such as the need for injections or strict dietary restrictions by being a small-molecule drug that can be taken with food or water at any time. Clinical trials showed weight loss of up to 11.1% in patients over two years on higher doses. Medicare coverage, which began in July 2026, is also helping increase access. Eli Lilly is investing heavily in manufacturing capacity for Foundayo and other small-molecule drugs through a $6.5 billion facility being built in Houston, part of its broader $27 billion U.S. expansion plan announced earlier this year.
Topics: GLP-1 Therapy Market Growth Oral Medication Pharmaceuticals